Author

Mark A Sloan

Boston University School of Medicine - Cited by 2,856 - AL Amyloidosis - Clinical Trials - IVC Filter outcome research

Biography

He is affiliated to Department of Emergency Medicine, St. Joseph London Emergency Department, Lexington, KY, USA. He is a recipient of many awards and grants for his valuable contributions and discoveries in major area of subject research. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect in his wide range of publications in various national and international journals
Title
Cited by
Year
SARS-CoV-2 Infection–Associated Hemophagocytic Lymphohistiocytosis: An Autopsy Series With Clinical and Laboratory Correlation
A Prilutskiy, M Kritselis, A Shevtsov, I Yambayev, C Vadlamudi, Q Zhao, ...American journal of clinical pathology 154 (4), 466-474, 2020202
130
2020
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study
V Sanchorawala, S Sarosiek, A Schulman, M Mistark, ME Migre, R Cruz, ...Blood, The Journal of the American Society of Hematology 135 (18), 1541-1547, 2020202
114
2020
Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis
A Staron, EJ Burks, JC Lee, S Sarosiek, JM Sloan, V SanchorawalaBlood advances 4 (5), 880-884, 2020202
40
2020
Presence of t (11; 14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen
B Dumas, H Yameen, S Sarosiek, JM Sloan, V SanchorawalaAmyloid 27 (4), 244-249, 2020202
25
2020
Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis
R Szalat, S Sarosiek, A Havasi, D Brauneis, JM Sloan, V SanchorawalaLeukemia 35 (3), 916-919, 2021202
22
2021
Prevalence and prognostic value of D‐dimer elevation in patients with AL amyloidosis
A Pudusseri, V Sanchorawala, JM Sloan, KM Bever, G Doros, S Kataria, ...American journal of hematology 94 (10), 1098-1103, 2019201
15
2019
The role of kidney transplantation in monoclonal Ig deposition disease
A Angel-Korman, L Stern, Y Angel, S Sarosiek, H Menn-Josephy, ...Kidney International Reports 5 (4), 485-493, 2020202
14
2020
Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis
S Sarosiek, L Zheng, JM Sloan, K Quillen, D Brauneis, V SanchorawalaBlood Cancer Journal 10 (8), 88, 2020202
12
2020
Vaccine-induced immune thrombotic thrombocytopenia with concurrent arterial and venous thrombi following Ad26. COV2. S vaccination
A Charidimou, S Samudrala, AM Cervantes-Arslanian, JM Sloan, ...Journal of Stroke and Cerebrovascular Diseases 30 (12), 2021202
9
2021
Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab
RE Szalat, J Gustine, JM Sloan, CV Edwards, V SanchorawalaAmerican Journal of Hematology 97 (1), 79-9, 2022202
8
2022
Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripes
A Staron, Y Kataria, DL Murray, JM Sloan, V SanchorawalaAmerican Journal of Hematology 95 (2), E45-E4, 2020202
8
2020
The effect of anticoagulant choice on venous thromboembolism recurrence and bleeding in sickle cell disease
VK Gupta, R Strykowski, B Scarpato, R Lawrence, SL Khan, J Patel, ...American Journal of Hematology 95 (10), E279-E281, 2020202
6
2020
Risk factors for Venous Thromboembolism and clinical outcomes in adults with sickle cell disease
B Scarpato, R Strykowski, R Lawrence, SL Khan, J Newman, MR Spring, ...Thrombosis Update 6, 100101, 2022202
5
2022
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study
JN Gustine, A Staron, RE Szalat, LM Mendelson, T Joshi, FL Ruberg, ...American Journal of Hematology 97 (9), 1189-1199, 2022202
4
2022
Successful transition from bortezomib subcutaneous (SubQ) to generic intravenous (IV) bortezomib: cost savings initiative with global economic impact
R Jhaveri, V Sanchorawala, JM Sloan, A Lerner, S Sarosiek, B ShahBlood 14, 4758, 2019201
3
2019
Nonsecretory recurrence of multiple myeloma presenting as sixth nerve palsy secondary to clival plasmacytoma
AR Kaufman, K Quillen, AG Distefano, JM SloanJournal of Neuro-Ophthalmology 41 (1), e77-e78, 2021202
3
2021
Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs
CJ Milrod, F Blevins, D Hughes, A Lerner, S Sarosiek, V Sanchorawala, ...Blood, The Journal of the American Society of Hematology 137 (1), 987-989, 010
2
2021
Safety, tolerability, and efficacy of selinexor in a patient with relapsed light chain (AL) amyloidosis
DM Hughes, S DeMari, H Hassan, V Sanchorawala, JM SloanClinical Lymphoma Myeloma and Leukemia 1 (5), e460-e463, 010
2
2021
Patients with Sickle Cell Disease and Venous Thromboembolism Experience Increased Frequency of Vasoocclusive Events
RC Lawrence, SL Khan, V Gupta, B Scarpato, R Strykowski, J Newman, ...Blood 134, 999, 01901
2
2019
Droxidopa for treatment of refractory orthostatic hypotension in patients with AL amyloidosis: A case series
JNR Lopez, LM Mendelson, T Joshi, D Hughes, MC Kaku, ...Blood 138, 4737, 010
2
2021

Referred From: https://scholar.google.com/citations?user=tl03X84AAAAJ&hl=en

Cited by
Citations 2856
h-index 26
i10-index 48
Recommended Journals
Open Access Journals